• Pembrolizumab prolongs survival in recurrent, metastatic head and neck squamous cell carcinoma

    8 days ago - By Healio

    CHICAGO - Pembrolizumab extended OS compared with standard chemotherapy for patients with relapsed or metastatic head and neck squamous cell carcinoma, according to randomized phase 3 study results presented at American Association for Cancer Research Annual Meeting.
    Researchers also reported “an enhanced benefit” with pembrolizumab for patients with PD-L1-expressing tumors.
    “These data - along with the safety data - are indeed showing a place for PD-1 inhibition in the context of head and neck cancer, and this warrants further investigation,”
    Read more ...